This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on Web of Science (5)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Ronald Prussick, MD, FRCPC; Alain Thibault, MD; Maria L. Turner, MD
Dermatology Branch; Oncology Branch; Dermatology Branch National Cancer Institute National Institutes of Health Bethesda, MD 20892

Arch Dermatol. 1993;129(5):644-645.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.—

Fluorouracil administered as a single agent has been the standard therapy for patients with metastatic colorectal carcinoma. This chemotherapeutic agent has multiple cutaneous side effects. We report a case of reactivation or "recall" of a previous toxic cutaneous reaction resulting from intravenous fluorouracil. This occurred in a patient with metastatic gastrointestinal carcinoma who received several cycles of intravenous fluorouracil and/or leucovorin followed by daily subcutaneous granulocyte-macrophage colony-stimulating factor. With each successive cycle, a more severe toxic erythema developed on the arm receiving the infusion. When the infusion site was switched to the opposite limb, a cutaneous flare occurred not only on the arm currently receiving the infusion but on the previously reactive, resting arm.

Report of a Case.—

A 43-year-old white man with adenocarcinoma of the colon (stage D) was entered in a phase I protocol of intravenous bolus fluorouracil (490 mg/m²) and leucovorin calcium (500 . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?